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LIM and SH3 protein 1 (LASP-1), initially identified from human breast cancer, is a specific focal adhesion protein involved in cell
proliferation and migration. In the present work, we analysed the effect of LASP-1 on biology and function of human ovarian cancer
cell line SKOV-3 using small interfering RNA technique (siRNA).Transfection with LASP-1-specific siRNA resulted in a reduced
protein level of LASP-1 in SKOV-3 cells. The siRNA-treated cells were arrested in G2/M phase of the cell cycle and proliferation of
the tumour cells was suppressed by 60–90% corresponding to around 70% of the cells being transfected successfully as seen by
immunofluorescence. Moreover, transfected tumour cells showed a 40% reduced migration. LASP-1 silencing is accompanied by a
reduced binding of the LASP-1-binding partner zyxin to focal contacts without changes in actin stress fibre and microtubule
organisation or focal adhesion morphology as observed by immunofluorescence. In contrast, silencing of zyxin is not influencing cell
migration and had neither influence on LASP-1 expression nor actin cytoskeleton and focal contact morphology suggesting that
LASP-1 is necessary and sufficient for recruiting zyxin to focal contacts.The data provide evidence for an essential role of LASP-1 in
tumour cell growth and migration, possibly through influencing zyxin localization.
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Ovarian cancer is the sixth most common cancer among women
worldwide, with estimated 190000 new cases and 114000 deaths
caused through this neoplasm each year (Parkin et al, 2001).
Epithelial ovarian cancer represents 90–95% of all ovarian
tumours (Auersperg et al, 2001; Quirk and Natarajan, 2005),
which is detected in 60.6% cases in advanced stages of disease
due to unspecific or absent symptoms in early stages. Although
tremendous efforts have been undertaken to improve the
therapeutic outcome, ovarian cancer still remains the most lethal
malignoma among gynaecological tumours of women in the
western world, given that only 35% of ovarian cancer patients
show a 5-year survival (Legge et al, 2005).
About 90% of all epithelial ovarian tumours are sporadic and are
diagnosed in women without germline mutations in known
susceptibility loci. However, the remaining cases are heritable.
Data from several international studies suggest that patients with a
loss of heterozygosity of the BRCA1 and BRCA2 genes, which are
located on 17q21 and found in hereditary forms of breast cancer,
have a 6–61-fold increased lifetime risk of ovarian cancer
compared with general population rates (Antoniou et al, 2003).
The Lim and SH3 domain protein LASP-1 was initially identified
from a cDNA library of breast cancer metastases. The gene was
also mapped to human chromosome 17q21 in a region that is
altered in 20–30% of human breast cancers (Tomasetto et al,
1995a,b), suggesting that it could play a role in tumour
development and metastasis of breast and ovarian cancer.
Human LASP-1 encodes a membrane-associated protein of 261
amino acids containing an N-terminal LIM domain, followed by
two actin-binding sites and a C-terminal src homology SH3
domain. The actin-binding domains in the core of the LASP-1
protein mediate an interaction between LASP-1 and actin at cell
membrane extensions, but not along the actin stress fibres
(Schreiber et al, 1998; Chew et al, 2002; Butt et al, 2003; Keicher
et al 2004; Nakagawa et al, 2006). The exact cellular function of
LASP-1 is still not known, but the protein has previously been
reported to localise within multiple sites of dynamic actin
assembly such as focal contacts, focal adhesions, lamellipodia,
membrane ruffles and pseudopodia (Tomasetto et al, 1995a; Chew
et al, 1998, 2000, 2002; Lin et al, 2004).
The SH3 domain at the C-terminus is involved in protein–
protein interactions through binding to proline-rich sequences,
specifically with zyxin, pallidin, lipoma preferred partner (LPP)
and vasodilator-stimulated phosphoprotein (VASP) (Keicher et al,
2004; Li et al, 2004; Rachlin and Otey, 2006).
Moreover, recent data showed that LASP-1 specifically interacts
via its nebulin-like repeats with Krp1, a focal adhesion protein
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sinvolved in cell migration. Mutation analysis of LASP-1
demonstrates that its SH3 domain is necessary for pseudopodial
extension and invasion (Spence et al, 2006). Thus the protein–
protein interactions mediated by the LIM and SH3 domains can be
regarded as scaffolds for the formation of complexes of higher
order.
LASP-1 is a cAMP- and cGMP-dependent protein kinase
substrate with a specific phosphorylation site on serine 146 (Butt
et al, 2003). In rabbit parietal cells, elevation of intracellular cAMP
by forskolin induced a partial translocation of LASP-1 to the
apically directed F-actin-rich intracellular canaliculus, which is the
site of active HCl secretion (Chew et al, 1998, 2000). Beyond this,
phosphorylation on serine 146 resulted in translocation of the
protein from the membrane to the cytosol and was followed by
reduced cell migration (Butt et al, 2003). It has also been shown
that the SH3 domain of LASP-1 interacts with the N-terminus of
Ableson tyrosine kinase and that phosphorylation of LASP-1 at
tyrosine 171 is associated with the loss of LASP-1 from focal
adhesions and the initiation of cell death, but without changes in
dynamic of migratory processes (Lin et al, 2004).
In addition, LASP-1 expression has been reported to be
increased in metastatic breast cancer, suggesting that overexpres-
sion of LASP-1 may be involved in the migratory process of these
cells (Tomasetto et al, 1995a). Surprisingly, both increase and
depletion of LASP-1 in COS-7, HEK293 and MCF-7 cells inhibited
basal and growth factor-stimulated cell migration (Lin et al, 2004).
Interestingly, recent work has shown, that knock-down of LASP-
1 in metastatic breast cancer cell lines BT-20 and MCF-7 results in
a strong inhibition of proliferation and migration and leads to a
reduction of zyxin at focal contacts through absence of LASP-1
(Grunewald et al, 2006).
In this study we demonstrate that LASP-1 is highly over-
expressed in ovarian cancer tissue and metastatic ovarian cancer
cell lines. Silencing of the LASP-1 gene by RNA interference in the
ovarian cancer cell line SKOV-3 reduced cell proliferation and
cell migration in vitro without influencing the actin cytoskeleton,
microtubule polymerisation and focal adhesion morphology.
Furthermore, the knock-down of LASP-1 severely affected zyxin
localisation.
MATERIALS AND METHODS
Tissue samples
The studies were performed with approval of the Ethics Committee
of the University of Wurzburg. Tissue samples of 26 archival cases
each of serous epithelial ovarian carcinomas with and without
invasive components (obtained from the Department of Pathology
of the University of Wurzburg and reviewed by a pathologist to
confirm the diagnosis), as well as two samples of ascitic fluid
containing ovarian cancer cells of women with metastatic ovarian
cancer were analysed.
Immunohistochemistry
For immunohistochemical staining procedures, endogenous per-
oxidase was blocked by incubation in 0.1% hydrogen peroxide in
PBS for 5min. The slides were then incubated with the polyclonal
anti-LASP-1 antibody (Butt et al, 2003) diluted 1:1000 in ‘antibody
diluent’ (DAKO, Hamburg, Germany), followed by the EnVision/
rabbit detection system (DAKO). Histogreen (Linaris, Wertheim,
Germany) was used as the chromogen and cells were counter-
stained with haematoxylin (Sigma, Deisenhofen, Germany).
Cell culture conditions
Cell lines (SKOV-3, OAW-42 and PA-1) were obtained from the
Cell Line Services (Heidelberg, Germany) and grown at 1 10
5
cellsml
 1in a plastic cell culture flask in a humidified incubator at
371C under 5% CO2 atmosphere in RPMI 1640 medium (PAA,
Linz, Austria) containing 10% heat-inactivated foetal bovine serum
(PAA) and 1% streptomycin/ampicillin (Invitrogen, Karlsruhe,
Germany). For primary tumour cell culture, effusions (20–500ml)
were centrifuged, cell pellets washed twice in PBS (Biochrom,
Berlin, Germany),resuspended in RPMI 1640 medium supplemen-
ted as described and then seeded on the bottom of a cell culture
flask. After 1h, all nonadherent (mostly leucocytes) cells were
washed away and adherent tumour cells cultured in RPMI 1640/
10%FCS/streptomycin/ampillicin. Contaminating fibroblasts were
deleted by trypsin treatment every other day and the remaining
tumour cell monolayer was cultured until homogeneous morphol-
ogy of the cells (passage 3–4) was reached. Cells were checked
routinely and found to be free of contamination by bacteria or
fungi.
small interfering RNA preparation and transfection
Expression of human LASP-1 was knocked down with siRNA
duplexes targeting the sequence 50-AAG GTG AAC TGT CTG GAT
AAG-30 (bases 49–69), 50-CUUAUCCAGACAGUUCACCdTdT-30.
The control siRNA 50-AGAGAUGUAGUCGCUCGCUdTdT-30 tar-
geting no known mRNA sequence was used as a control. Both
siRNAs were obtained from Dharmacon RNA Technologies
(Lafayette, CO, USA). The siControl nontargeting siRNA from
Dharmacon could not be used in our cell system owing to toxic
effects. A BLAST search against the complete human and murine
genome verified that the selected sequences were specific for the
respective target gene.
Cells in the exponential phase of growth were plated in six-well
plates at a density of 0.5 10
5 cells/well, grown for 24h and
transfected with 1mg (60nM) siRNA in reduced serum medium
OPTI-MEM-I (Gibco, Paisley, UK) at 30–50% confluence. For
the formation of the siRNA–lipid complexes, 3ml siRNA stock
solution (20mM) was diluted in 100ml OPTI-MEM, mixed with 3ml
Metafectene (Biontex, Munich, Germany) in 100ml OPTI-MEM and
incubated at room temperature for 17min. Subsequently, the
culture medium was removed and replaced by 1ml OPTI-MEM-I
and the siRNA–lipid complexes (1.2ml total volume). After 4h
incubation at 371C, 1.2ml of cell culture medium with 20% foetal
bovine serum was added, and incubation was continued for 36–
56h. For control cells, Metafectene alone (MOCK-transfection)
and/or 1mg scrambled control-siRNA were used.
Silencing of zyxin was achieved with Hs_ZYX_1_HP validated
siRNA at a final concentration of 10nM using HiPerfect transfec-
tion reagent (Qiagen, Hilden, Germany) according to the
manufacturer’s directions. For zyxin control experiments, non-
silencing control siRNA, Alexa Fluor 488 labelled, provided by
Quiagen, was used.
At least three independent experiments were performed for each
cell line, and representative results are shown.
Cell proliferation assay
For proliferation assay, cells were transfected as described. At the
time points indicated, cells were trypsinised and cell numbers were
determined by a Coulter counter (Beckman, Fullerton, CA, USA).
Experiments were performed in triplicate for each time point. Cell
viability was evaluated by counting trypan blue-positive and
-negative cells under a phase-contrast microscope (Zeiss Axiovert,
Aalen, Germany).
Western blot analysis
For Western blotting, cells were prepared by lysing in Laemmli
sample buffer and equal amounts of protein, according to the cell
count, were resolved by 12% SDS–PAGE. After blotting on
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snitrocellulose membrane and blocking with 3% nonfat dry milk in
10mM Tris, pH 7.5, 100mM NaCl and 0.1% (w/v) Tween 20, the
membrane was first incubated with the antibodies raised against
LASP-1 (1:10000) (Butt et al, 2003), caspase-3 (1:1000) (New
England Biolabs, Frankfurt, Germany) or mouse zyxin hybridoma
supernatant (1:100; kind gift from Dr J Wehland, GBF Braunschweig,
Germany; Rottner et al, 2000), followed by incubation with
horseradish peroxidase-coupled goat anti-rabbit IgG or goat anti
mouse IgG (Biorad, Munich, Germany), diluted 1:5000 and
detection by ECL or ECL plus (Amersham Biosciences, Freiburg,
Germany). Protein bands were visualised by autoradiography.
Quantification of the signals was carried out by densitometry using
the Odyssey system (Li-Cor, Bad Homburg, Germany).
FACS
For cell cycle analysis, SKOV-3 cells were harvested 48h after
LASP-1 siRNA transfection. The cells were pelleted and stained
with DAPI (Sigma) at a final concentration of 2mgml
 1 in
permeabilisation buffer containing 0.1 M Tris—HCl, pH 7.4,
0.154 M NaCl, 0.5mM MgCl2,1 m M CaCl2, 0.1% NP-40 and 0.2%
BSA in ddH2O for 30min at 41C in the dark. Bivariate flow
histograms were recorded on an analytical, dual-laser-equipped
cytometer (LSR1, Becton Dickinson Biosciences, Heidelberg,
Germany) using UV excitation. Resulting cell cycle distributions
were quantified with the MPLUS AV software (Phoenix Flow
Systems, San Diego, CA, USA). For technical details, see Schindler
and Hoehn (1999).
Two-dimensional-gelelectrophoreses and mass
spectrometry
Isoelectric focusing for two-dimensional (2D) gel electrophoresis
was performed using the Protean IEF cell from Biorad (Munich,
Germany) according to the instructions of the manufacturer. The
SKOV-3 homogenate (about 200mg protein) was solubilised for
15min by sonication in 320ml lysis buffer containing 7 M urea, 2 M
thiourea, 4% (w/v) CHAPS, 15mM DTT (electrophoresis grade),
0.5% carrier ampholytes, pH 3–10. Pellet homogenate was loaded
on a 17-cm immobilised IPG strip, pH 3–10 and resolved
overnight at 50V. Focussing was carried out for 1h at 250V, 1h
at 500V and 15h at 7000V. After equilibration in 50mM Tris, pH
8.9, 6 M urea, 30% (w/v) glycerol and 2% (w/v) SDS, gels were
immediately applied to a vertical 10% SDS gel without a stacking
gel. Electrophoresis was carried out at 81C with a constant current
of 40mA per gel. Proteins were visualised by Coomassie Brilliant
Blue R-250 (Sigma) staining.
Gel pieces were washed two times alternating with 50mM
ammonium hydrogen carbonate buffer and 25mM ammonium
hydrogen carbonate buffer with 50% acetonitrile. Proteins were
reduced with 10mM DTT for 30min at 561C and subsequently
alkylated by incubation with 20mM iodoacetamide at room
temperature for 30min. Again samples were washed as described
before. Gel pieces were shrunken in a SpeedVac (Thermo Electron,
Dreieich, Germany) and rehydrated with 12.5ng of trypsin in
50mM ammonium hydrogen carbonate buffer. Digestion was
performed by incubation at 371C overnight. The resulting peptides
were extracted by application of 15ml of 5% formic acid for 10min.
Separation of complex peptide mixtures was achieved by using
reversed-phase chromatography. For nano-LC-ESI-MS/MS experi-
ments, a setup consisting of an autosampler (Famos, Dionex,
Idstein, Germany) and precolumn concentration (Switchos,
Dionex) before nano-LC separation (Ultimate, Dionex) was used.
Precolumns (300-mm inner diameter 1-mm length) and separa-
tion columns (75mm inner diameter 150-mm length, C18
PepMapTM) were purchased from Dionex. Gradient elution was
performed using a linear gradient from 5 to 50% solvent B (84%
acetonitrile, 0.1% formic acid) during a period of 2h. Solvent A
was 0.1% formic acid in water. Separation was followed by rinsing
the column with 95% B for 5min before equilibration to 5%
solvent B before the next separation cycle.
Peptides were directly eluted into an ESI mass spectrometer. For
mass spectrometric analysis, an ESI linear ion trap LTQ (Thermo
Electron, Dreieich, Germany), using distal-coated fused silica tips
(New Objective, Woburn, MA, USA), spray voltage was set around
1800V. A survey scan (m/z 350–2000) was followed by five MS/MS
scans fragmenting the five most intensive peptide signals.
Mass spectra were transformed into peak lists in dta or mgf
format using the wo in-house software solution raw2dta (Boehm
et al, 2004). Generated data were processed in parallel with the
search algorithms SequestTM, Version 27 (Yates et al, 1995) and
MascotTM, Version 2.1.6 (Perkins et al, 1999). For sequence
alignment, the swissprot database from October 2005 was used.
As fixed modification, carbamidomethylation of cysteine residues
was used, and as variable modification oxidation of methionine
residues was selected. As filter criteria for Sequest we accepted in
the first instance only positive peptide hits with a minimum cross-
correlation factor of 2.5, a CN value of 0.25, and a preliminary
ranking of one. For the Mascot algorithm the minimum score was
set to 40 for each peptide. Only protein hits that were identified
with these parameters by both algorithms and had at minimum
two identified peptides were accepted. Additionally, all significant
hits were revised manually.
Immunfluorescence
For immunfluorescence microscopy, cells were grown on glass
chamber slides, fixed in 4% (w/v) paraformaldehyde in PBS,
permeabilised with 0.1% (w/v) Triton X-100 in PBS and then
stained with affinity-purified LASP-1 antibody (1:2000, 1h),
followed by secondary Cy3-labelled anti-rabbit antibody (1:500,
30min) (Dianova, Hamburg, Germany) or mouse zyxin hybridoma
supernatant (1:10, 2h), followed by secondary Cy2 labelled goat-
anti mouse antibody (1:500, 1h) (Dianova). Oregon green
phalloidin (Molecular Probes, Leiden, The Netherlands) was used
for actin staining. Tubulin was stained with an anti-a-tubulin
antibody (3mgml
 1) (Calbiochem, Darmstadt, Germany). DNA
was counterstained with DAPI (1:2500) (Calbiochem) for 2min.
Migration experiments
Cells were cultured in medium in 25cm
2 flasks to approximately
30–40% confluence and transfected with 10nM zyxin siRNA or
30nM LASP-1 siRNA (Keicher et al, 2004) using 10ml Metafectene.
After 48h incubation and overnight starving, 1 10
5 cells in 100ml
incubation medium (with 1mM MgCl2) were seeded in the upper
chamber of BSA-coated 8mM pore size transwell Boyden chambers
(Corning star, Cambridge, MA, USA). Cells were allowed to
migrate through the porous membrane for 4h at 371C. Cells
remaining at the upper surface were completely removed using a
cotton carrier. The lower surfaces of the membranes were then
stained in a solution of 1% (w/v) crystal violet in 2% ethanol for
30s and rinsed afterwards in distilled water. Cell-associated crystal
violet was extracted by incubation in 10% acetic acid for 20min
and measured at 595nm absorbance.
RESULTS
LASP-1 is overexpressed in ovarian cancer tissue
To assess the role of LASP-1 in ovarian cancer, we examined its
expression in 26 ovarian cancer samples from different patients
with or without invasive components. Immunohistochemistry
clearly allowed to localise LASP-1 expression in 14 out of 26
malignant ovarian tissues (53.8%). Strong immunoreactivity was
observed in nine cases (Figure 1A), whereas five probes showed a
LASP-1 in human ovarian cancer
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(46.2%) were considered to be LASP-1 negative.
Normal benign epithelial cells were LASP-1-negative in all
ovarian tissues even when malignant epithelial cancer cells close to
these normal epithelial cells displayed a strong positivity for LASP-
1 (Figure 1D).
In analogy to previous findings in myoepithelial cells of human
breast tissue (Grunewald et al, 2006), a massive overexpression in
vascular smooth muscle cells could be observed (Figure 1C).
LASP-1 is strongly expressed in ovarian cancer cell lines
In order to study the significance of LASP-1 overexpression in
ovarian cancer, we tested three ovarian cancer cell lines (SKOV-3,
OAV-42 and PA-1) as well as two primary cell cultures derived
from ascitic fluid of patients with peritoneal metastatic ovarian
cancer for LASP-1 expression. Loading was standardised to 3 10
5
cells per slot and controlled by b-actin loading control signal
intensity.
Only the three ovarian cancer cell lines showed a high LASP-1
signal, whereas the two primary cell lines were LASP-1 negative
(Figure 2). Interestingly, the solid primary ovarian cancer tissue
preparations of these two patients showed intensive LASP-1
staining (data not shown).
We chose SKOV-3 cells as a cellular model for ovarian cancer
because in these cells the BRCA1 and BRCA2 genes, which are
located next to the LASP-1 gene on chromosome 17q21, are
upregulated (Rauh-Adelmann et al, 2000).
Silencing of LASP-1 in SKOV-3 cells inhibits proliferation
in vitro
To investigate the function of LASP-1 in the ovarian cancer cell
line SKOV-3, we performed a knock-down of the gene using the
powerful RNAi technique. The effect of siRNA transfection on the
expression of LASP-1 was followed by Western blot analysis 0, 24,
48 and 53h after transfection. The amount of LASP-1 protein,
standardised to b-actin, was reduced up to 58% after 48h (Figure 3,
lower panel) compared with the control siRNA-transfected control
cells. This corresponds to around 70% of the cells being
transfected successfully as seen by immunofluorescence. Parallel
to the protein knock-down, we observed a slower proliferation rate
in LASP-1 siRNA-transfected cells compared with control cells
(Figure 3, upper panel). The viability of cells was similar in both
cultures as trypan blue staining detected no more than 5–8% dead
cells in all experiments. To test whether the decreased proliferation
could be due to apoptosis, we carried out a Western blot analysis
with an anti-caspase-3 antibody. The antibody recognises both the
non-active pro-caspase-3 (38kDa) and the active cleaved caspase-3
protein (17kDa). As shown in Figure 4B, treatment of SKOV-3
cells with the LASP-1 siRNA duplex produced no active caspase-3,
Figure 1 Immunohistochemical staining of cancerous ovarian tissue. LASP-1 was detected using anti-LASP-1 rabbit polyclonal antibody in paraffin-
embedded tissue samples. (A) Ovarian cancer tissue with two cystic structures containing malignant cells, which are strongly LASP-1 positive (arrow), and an
LASP-1-negative lymphocytic inflammation (star). (B) Infiltrating tumour cells displaying medium LASP-1 expression (arrow). (C) Three ductus with
malignant epithelial cells and medium LASP-1 expression and a blood vessel in longitudinal cut with vascular smooth muscle cells showing strong LASP-1
positivity (arrow). (D) Two epithelial strata separated through connective tissue. The arrow indicates malignant LASP-1-positive and the star benign LASP-1-
negative epithelial cells. LASP-1
þ cells are stained in brown (DAB). All sections were counterstained with haematoxylin.
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Figure 2 Western blot of different ovarian cancer cell lines. A total of
200000 cells from established ovarian cancer cell lines (SKOV-3, OAW-42
and PA1), as well as primary cells derived from ascitic fluid of two patients
(ascitis T and B) with peritoneal metastatic ovarian cancer, were analysed
for LASP-1 expression by Western blot. Loading was controlled by b-actin
Western blot.
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proliferation.
Downregulation of LASP-1 induces G2 phase accumulation
in SKOV-3 cells
We next analysed cell cycle distributions of siRNA-treated SKOV-3
cells using flow cytometry. After incubation with LASP-1 siRNA
for 48h, the proportion of cells accumulating in the G2 phase
amounted to 19.4% (Figure 4A), whereas the same cells treated
with Metafectene alone (MOCK transfection) as a control had only
6.7% G2 phase proportion. Conversely, the G1 fraction decreased
from 73.4% in MOCK-treated cells to 48% in LASP-1-silenced
SKOV-3 cells. The S phase fraction for siRNA LASP-1-treated cells
was 32.6% and for MOCK transfection 19.9%, respectively. Similar
results were obtained in three independent experiments indicating
that in LASP-1-silenced SKOV-3 cells mitotic progression cannot
proceed normally. However, immunfluorescence staining of
a-tubulin and DNA in the cells reveald no reduced tubulin
polymerisation in the LASP-1-silenced cells arrested in G2/M phase
(Figure 4C).
Knock-down of LASP-1 results in protein changes of
glycolytic metabolism and cell cycle regulation
Under LASP-1 knock-down conditions it might be necessary for
the maintenance of cellular steady state to upregulate alternative
proteins to overcome functionally the loss of LASP-1. We used 2D
gel electrophoreses to resolve the homogenate of SKOV-3 cells
before and after LASP-1 silencing. Subtractive analysis of the two
gels showed a high degree of similarity, however, at least five
proteins have been identified to become up-, or respectively
downregulated by LASP-1 silencing in three independent experi-
ments: pyruvate kinase (up), enolase-1 (down), glucose dehydro-
genase (down), 14-3-3 (up) and heat-shock protein (Hsp) 27 (up)
(Figure 5).
Silencing of LASP-1 results in reduced zyxin binding to
focal adhesions
LASP-1 has previously been shown to localise to sites of cell
adhesion and to interact with zyxin and actin (Chew et al, 2002;
Li et al, 2004). To assess whether silencing of LASP-1 affects these
binding partners, siRNA-treated SKOV-3 cells were stained with
phalloidin green against actin or mouse anti-zyxin hybridoma
supernatant. In LASP-1 siRNA-transfected cells, zyxin was absent
from focal adhesions, whereas the cellular level of zyxin remained
unchanged as confirmed by Western blot analysis (Figure 6).
However, absence of zyxin from focal contacts did not lead to
changes in focal adhesion morphology as visualized by vinculin
staining (Figure 6). Likewise, actin filament assembly was not
disturbed (Figure 6), despite less actin bundles, a blurred network
of shorter filaments and some F-actin aggregates are typical for
highly metastatic cancer cell lines (Liu et al, 2004).
Silencing of zyxin does not change LASP-1 localisation or
focal adhesion morphology
As knock-down of LASP-1 is altering zyxin localisation, we further
assessed the interaction of both proteins in a reverse experiment
by knocking down zyxin. Transfection of SKOV-3 with zyxin-
specific siRNA dramatically reduced zyxin expression down to
10–20%, while the cellular level of LASP-1 and b-actin remained
unchanged as confirmed by Western blot analysis (Figure 7).
Immunofluorescence of the zyxin-silenced cells illustrated lack
of zyxin at the focal adhesions without altering the position of
LASP-1 (Figure 7), suggesting that LASP-1 is necessary for the
positioning and recruiting of zyxin to focal adhesions. Other focal
adhesion proteins, for example, b-actin (Figure 7) and vinculin
(data not shown), were unaffected by the zyxin knock-down.
Silencing of LASP-1, but not of zyxin, decreases cell
migration
Although the exact function of LASP-1 is not known, recent results
suggest an important role for this protein in cell adhesion and
migration (Butt et al, 2003; Lin et al, 2004; Grunewald et al, 2006;
Nakagawa et al, 2006). To directly examine the relevance of
LASP-1 for cell motility we performed migration experiments in a
modified Boyden chamber with SKOV-3 cells either transfected
with LASP-1 siRNA or zyxin siRNA to downregulate the respective
protein. Cells were seeded in the upper chamber of a transwell
polycarbonate membrane. After 4h, those cells that had migrated
through the porous membrane were counted. Depletion of LASP-1
in SKOV-3 cells strongly reduced cell migration, while zyxin
knock-down had no influence on cell migration (Figure 8)
suggesting that LASP-1 acts as a positive regulator for cell motility.
DISCUSSION
Cell migration and controlled assembly and disassembly of focal
adhesions are highly integrated multistep processes and a central
feature in the molecular pathology of cancer (Ridley et al, 2003).
To date, more than 50 different adhesion proteins that regulate the
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Figure 3 Silencing of LASP-1 in SKOV-3 cells inhibits proliferation. A
total of 40000 cells of the SKOV-3 cells were plated and allowed to grow
for 24h (up to 40% confluence). Small interfering RNA LASP-1 was
transfected into cells in a concentration of 60nM. Cells were harvested after
0, 24, 44 and 53h of siRNA treatment. Control cells were treated with
control siRNA. Upper panel: treatment with siRNA LASP-1 impairs SKOV-
3 cell proliferation. After the indicated periods of time, the cells were
harvested, and their total number was determined using a Coulter counter.
Lower panel: Densitometric quantification and Western blot analysis of
LASP-1 expression standardised to b-actin at the corresponding time
points shows a reduction of LASP-1 expression of about 60% 44h after
transfection with siRNA LASP-1.
LASP-1 in human ovarian cancer
TGP Grunewald et al
300
British Journal of Cancer (2007) 96(2), 296–305 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
srate and organisation of actin polymerisation and focal adhesion
turnover in protrusion have been identified.
In earlier publications, overexpression of LASP-1 mRNA in
metastatic lymph nodes derived from breast cancer patients, as
well as the co-amplification of the gene together with HER-2/neu
(c-erbB2) were demonstrated (Chew et al, 1998; Legge et al, 2005).
Two additional observations underscore the importance of LASP-1
in cancer. First, altered expression of LASP-1 is associated with
the MLL gene in acute myeloid leukaemia (Strehl et al, 2003).
Second, recent studies have shown LASP-1 to be transcriptionally
upregulated in response to the morphogen Sonic Hedgehog
(Ingram et al, 2002).
Consistent with these data, we just recently described the
overexpression of LASP-1 to very high levels in breast carcinomas
and lymph node metastases (Grunewald et al, 2006). The
functional significance of LASP-1 in cancer metastasis is further
supported by the presented data showing high LASP-1 expression
in ovarian cancer tissue and reduced cell migration in ovarian
cancer cells depleted of LASP-1. The absence of LASP-1 in cultures
of primary ovarian cancer cells in contrast to established cell lines
may reflect a downregulation of LASP-1 in the nonmigratory
floating ascites cells which will be reverted after several passages of
adherent cell culture. Comparable observations are published for
LASP-1 in human mesenchymal stem cells showing an upregula-
tion of the protein during later passages (Sun et al, 2006).
During LASP-1 silencing we observed reduced cell cycle
progression and an induced G2/M phase accumulation of the cells
without disrupted normal mitotic microtubule polymerisation.
This was accompanied by the upregulation and downregulation
of several proteins. The differentially expressed proteins pyruvate
kinase, enolase-1 and glucose dehydrogenase are part of the
glycolytic metabolism and their regulation correlates well with
the cell cycle arrest in G2/M after LASP-1 silencing. Furthermore,
pyruvate kinase and glucose dehydrogenase have been suspected
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Figure 4 LASP-1 siRNA treatment of SKOV-3 cells induces G2 phase accumulation without triggering apoptosis. (A) SKOV-3 cells were transfected with
siRNA LASP-1 and transfection reagent Metafectene or treated only with Metafectene (MOCK transfection). After 48h, the cells were harvested and
prepared for flow cytometric cell cycle analysis. LIM and SH3 protein 1 (LASP-1) siRNA-treated cells show G2 phase accumulation as opposed to the same
cells with MOCK transfection. (B) Several hours after siRNA LASP-1 treatment, cells were harvested and prepared for Western blot analysis using an anti-
caspase-3 antibody, the antibody recognises both the nonactive pro-caspase-3 (38kDa) and the active cleaved caspase-3 protein (17kDa). No active
caspase-3 could be detected. (C) Immunfluorescence of LASP-1 (red), a-tubulin (green) and DNA (blue) of siRNA LASP-1-transfected (*) and
nontransfected SKOV-3 cells.
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sto be highly important for tumour cell metabolism (Altenberg and
Greulich, 2004). Pyruvat kinase is one of the proteins to be
upregulated in cancer cells gaining energy by means of aerobic
glycolysis, which is a characteristic of a number of cancer entities
(Gatenby and Gillies, 2004). In addition, pyruvat kinase has been
identified as a proteomic marker of cancer progression in breast
cancer (Isidoro et al, 2005). The glycolytic enzyme enolase-1 as
well as HSP27, two additional proteins identified in the 2D-gel
experiments, are associated with high metastatic activity in breast
cancer cells (Espana et al, 2005; Zhang et al, 2005).
14-3-3, found to be upregulated after LASP-1 depletion in
ovarian cancer cells, has been implicated in cell cycle deregulation.
The 14-3-3 proteins are a family of highly conserved DNA-binding
proteins, which associate with the centrosomes during mitosis and
are inhibitors of G2/M progression at the mitotic and G2 cell cycle
checkpoint (Pietromonaco et al, 1996; Wang and Shakes, 1996;
Hermeking et al, 1997; Peng et al, 1997; Alvarez et al, 2002).
Overexpression of 14-3-3 led to cell cycle arrest in cell culture
models (Tzivion et al, 2006) and, therefore, might contribute to the
observed G2 arrest in ovarian cancer cells lacking LASP-1.
Heat-shock proteins are molecular chaperons and are induced
during cellular stress. Upregulation of HSP27 after LASP-1
silencing correlates well with increased survival by inhibiting key
effectors of the apoptotic pathway (Concannon et al, 2003).
So far, the identified proteins are regulated in response to cell
cycle arrest, but do not substitute for LASP-1 after silencing.
Recently, several LASP-1-binding partners have been identified.
Along with zyxin (Li et al, 2004) and actin (Schreiber et al, 1998),
LASP-1 interacts with Krp1 (Spence et al, 2006), palladin (Rachlin
and Otey 2006), lipoma-preferred partner (LPP) and VASP
(Keicher et al, 2004), which all can influence actin filament
dynamics and pseudopodial elongation. In the case of palladin,
LPP and zyxin, the binding occurs between the C-terminal SH3
domain of LASP-1 and the N-terminal proline-rich domains of
these proteins, whereas in the case of Krp1, binding is observed
between the nebulin-like repeats of LASP-1 and the N-terminal
BTB/POZ domain of Krp1. The interaction of LASP-1 and Krp1 is
crucial for pseudopodial elongation in fibroblasts in absence of
fibronectin and results in their colocalisation with F-actin at the
tips of extending pseudopodia (Spence et al, 2006).
Zyxin is localised primarily at focal adhesion plaques and plays
a central role in actin filament polymerisation in mammalian cells
(Beckerle, 1997).
Silencing of zyxin in HeLa cells resulted in significantly
reduced actin stress fibres (Griffith et al, 2005), whereas under
cyclic stretch zyxin only dissociated from focal contacts and
accumulated in the nucleus, without affecting vinculin or actin
filaments (Cattaruzza et al, 2004). Recent data show that in
genetically zyxin-deficient fibroblasts, focal adhesions are depleted
from Mena and VASP, and that cells lacking zyxin display deficits
in actin cytoskeleton remodelling (Hoffman et al, 2006). In our
immunflourescence experiments with LASP-1-deficient SKOV-3
cells, we observed a diffuse cytoplasmic localiation of zyxin
without protein loss and without changes in neither vinculin
distribution nor actin stress fibre organisation, emphasising the
importance of LASP-1 for binding and recruiting zyxin to focal
adhesions.
The loss of zyxin at the sites of focal contacts without changing
cellular zyxin protein levels is not restricted to cancer cells, but was
also observed in human umbilical vein endothelial cells (Grune-
wald et al, 2006). Interestingly, in these cells, zyxin could still be
detected along the actin stress fibres, indicating the potential
existence of another zyxin-recruiting protein along actin stress
fibres since earlier results detected LASP-1 only in the focal
adhesion plaques (Chew et al, 2002; Butt et al, 2003).
In our zyxin knock-down experiments, neither changes in
LASP-1 localisation, actin cytoskeleton, microtubule polymerisa-
tion nor vinculin distribution were detectable suggesting that zyxin
does not change focal adhesion morphology. This is concordant
with the fact that genetically zyxin-deficient fibroblasts show even
enhanced adhesion to surface and increased integrin expression
(Hoffman et al, 2006). In synopsis, our LASP-1 and zyxin silencing
studies have demonstrated that LASP-1 is necessary for recruiting
zyxin to focal contacts.
The decreased cell motility after LASP-1 silencing can be
explained by the functional loss of zyxin as a scaffolding protein
that facilitates the formation of molecular complexes to promote
site-specific actin assembly required for cell migration. This is in
agreement with previous findings using a nongenetic approach
and injecting a peptide derived from the N-terminus of zyxin to
displace zyxin from its normal subcellular location thus leading
to reduced cell migration (Drees et al, 1999). On the other hand,
the knock-down of zyxin in SKOV-3 cells had no influence on cell
migration while genetically zyxin-deficient fibroblasts display
enhanced migration (Hoffman et al, 2006). These contrary effects
have not been fully elucidated yet.
14-3-3
Enolase-1
Glucose 
dehydrogenase
Figure 5 Two-dimensional gel of SKOV-3 proteins after LASP-1 silencing. Sections are showing differences between cellular proteins from control (upper
panel) and LASP-1 knock-down (lower panel) SKOV-3 cells. Proteins were separated on nonlinear IPG-strips, pH 3–10. Two dimensional gels were stained
with Coomassie blue. Proteins were identified following tryptic digestion and analysis of the resulting peptides by ESI-MS/MS.
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sRecent work has shown that zyxin also shuttles through the
nucleus – most likely by association with other LIM proteins – and
may regulate gene transcription (Nix et al, 2001; Wang and
Gilmore, 2003; Kadrmas and Beckerle, 2004). During mitosis, a
fraction of zyxin becomes associated with the tumour suppressor
h-warts at the mitotic apparatus (Hirota et al, 2000). h-warts is a
key player in mitosis in mammalian cells and loss of its function
disrupts normal cell cycle regulation, possibly leading to tumour
development (Iida et al, 2004). In SKOV-3 cells transfected with
LASP-1 siRNA, zyxin has been shown to dissociate from focal
adhesion plaques and to distribute diffusely into the cytoplasm. It
is, therefore, likely that part of zyxin enters the nucleus, binds to
h-warts and leads to G2 cell cycle arrest and inhibition of
proliferation as observed after LASP-1 silencing.
Interestingly, in Ewing tumour cells, zyxin is only expressed at
very low levels and remains diffusely distributed throughout the
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Figure 6 LIM and SH3 protein 1 (LASP-1) is required for zyxin localisation at focal adhesions. Immunfluorescent images of LASP-1, zyxin, vinculin and
b-actin in siRNA LASP-1-treated SKOV-3 cells. Focal adhesions are marked with white arrows. Positions of downregulated cells are marked with stars.
Western blot (WB) analysis to assess LASP-1 and zyxin levels in the LASP-1 siRNA and control siRNA-treated SKOV-3 cells were performed from the
corresponding immunofluorescent cell extracts.
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scytoplasm instead of concentrating in actin-rich dynamic struc-
tures. Zyxin gene transfer into EWS-FLI1-transformed fibroblasts
elicits reconstitution of zyxin-rich focal adhesions and leads to
decreased cell motility and inhibition of anchorage independent
tumour growth, indicating that zyxin has tumour suppressor
activity in these cells (Amsellem et al, 2005).
Similar to findings in human breast cancer (Grunewald et al,
2006), our immunofluorescence experiments have shown that
absence of LASP-1 in focal contacts dramatically influences zyxin
distribution. In reverse, tumour cells, that are overexpressing
LASP-1, could functionally inhibit zyxin from shuttling into the
nucleus and acting as a tumour suppressor through increased
recruiting of zyxin to focal contacts by LASP-1. In summary, our
observations suggest an expanded role for LASP-1 in proliferation
and cancer cell migration. Further studies will define the potential
of LASP-1 as an independent marker for diagnosis of cancer, as
well as a marker for prognosis of this disease.
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